Related Experiment Video
Updated: Jul 20, 2026
06:57
Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis
Published on: June 14, 2019
Chapter 10: New dimensions in cervical cancer screening
Jack Cuzick1, Marie Helene Mayrand, Guglielmo Ronco
1Cancer Research UK Centre for Epidemiology, Mathematics and Statistics, Wolfson Institute of Preventive Medicine, Charterhouse Square, London, United Kingdom. jack.cuzick@cancer.org.uk
Vaccine
|September 5, 2006
Summary
Human papillomavirus (HPV) testing offers higher sensitivity for cervical cancer screening than cytology. Strategies are explored to optimize HPV testing, especially in diverse healthcare settings, balancing accuracy and resource use.
Area of Science:
- Gynecology
- Oncology
- Infectious Diseases
Background:
- Cervical cancer screening relies on cytology and Human Papillomavirus (HPV) testing.
- HPV testing shows higher sensitivity but lower specificity compared to cytology.
- Optimal implementation of HPV testing in primary screening requires further investigation.
Purpose of the Study:
- To evaluate the role of HPV testing in primary cervical cancer screening.
- To explore strategies for managing HPV testing's lower specificity.
- To discuss the implications of HPV as a sexually transmitted infection in screening.
Main Methods:
- Review of current HPV testing capabilities and limitations.
- Analysis of different screening and triage strategies using HPV testing.
- Examination of adjunct markers (e.g., HPV typing, viral load, p16, mRNA, cdc6, mcm5) to improve specificity.
- Consideration of microarray technologies for novel diagnostics.
Main Results:
- HPV testing is a sensitive primary screening tool, with cytology useful for triage.
- Alternative approaches are needed for settings with limited resources, focusing on rapid testing and immediate treatment.
- Specific HPV types (16, 18/45) may require distinct management.
- Viral load and cellular markers (p16, mRNA, cdc6, mcm5) show potential for enhancing specificity.
Conclusions:
- HPV testing is a viable primary screening modality, adaptable to different healthcare infrastructures.
- Further research into adjunct markers and rapid diagnostics can improve HPV testing's performance and clinical utility.
- Addressing patient anxiety related to HPV as an STI is crucial for successful screening programs.